Trial Profile
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 09 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Oct 2022 Planned End Date changed from 15 Sep 2022 to 15 Sep 2023.
- 11 Jul 2022 Planned End Date changed from 31 Dec 2025 to 15 Sep 2022.